Merck

Qure AI is a healthtech startup that uses artificial intelligence assistance for medical imaging diagnostics. The company's mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients. Qure AI was founded in 2016 and is based in Mumbai, Maharashtra.

CancerIQ provides a precision prevention platform that empowers healthcare providers to engage patients, stratify risk and ensure adherence with the latest evidence-based strategies to get ahead of cancer. It offers a robust content library of evidence-based guidelines and risk models to help providers interpret data and navigate patients to the appropriate genetic testing, screening, or treatment interventions.

Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets. Koneksa currently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2015 and is based in New York, United States.

Verana Health is a digital health data company that delivers insights from unfiltered healthcare data with integrity to connect the dots between patient care and clinical research. Verana Health is exclusively entrusted by key specialty medical societies to manage data from real-world healthcare settings across more than 20,000 healthcare providers and 70 electronic health record systems. Its healthcare data ecosystem is powered by VeraQ™, a clinician-directed and AI-enhanced population health data engine that securely powers a data integrity feedback loop of nearly a half-billion raw, point-of-care health encounters. By applying advanced analytics to proprietary, curated datasets, Qdata™, Verana Health helps life sciences partners enhance evidence generation and speed clinical research that promote physicians’ quality of care and patients’ quality of life. For more information, visit www.veranahealth.com.

Transcarent is a consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, health guides, and data science, the company helps consumers with unbiased information, trusted guidance, and access to high-value care.

Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.

Octave is a clinical platform developer who is working to create a new paradigm of multiple sclerosis care by generating, analyzing, and combining data. The platform of the company provides an integrated and multi-dimensional approach to lowering total cost of care by optimizing healthcare medications and utilization, allowing pharma to optimize the entire lifecycle of drug discovery and development, clinical trials, and post-marketing with real-world evidence.

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Transcarent is a consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, health guides, and data science, the company helps consumers with unbiased information, trusted guidance, and access to high-value care.

PathAI’s services solve challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making accurate diagnoses for every patient, every time. The company was founded in 2016 and is based in Boston, Massachusetts.

M2Gen® is a health informatics solutions company focused on accelerating the discovery, development and delivery of personalized medicine. Our Company was founded in 2006 at the Moffitt Cancer Center to operationalize the Total Cancer Care® Protocol, a unique approach to studying patients throughout their lifetime. In this effort, we partner with the nation’s leading cancer centers via the Oncology Research Information Exchange Network (ORIEN).

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

VelosBio is an operator of a clinical-stage biopharmaceutical company intended to develop novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. The company's ROR1-directed therapeutics is a cell-surface protein that is expressed on many hematologic and solid tumors but is absent from normal tissues, making it an attractive tumor-specific therapeutic target and has demonstrated positive preclinical results in tumor models, enabling institutions to get novel targeted therapies for use as monotherapy or in combination across a broad range of cancers. It was founded in 2017 and headquartered in San Diego, California.

Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets. Koneksa currently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2015 and is based in New York, United States.

A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.

To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions that matter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond.

Ayogo is a global leader in the application of behavioral psychology and social gaming to improve health outcomes for patients. Healthier patients improve financial outcomes. Insurers, healthcare providers, ACOs and pharmaceutical companies are Ayogo’s clients. All of our projects begin with meaningful collaboration with patients, end-users and clients. Our corporate culture fosters excellence and thoughtful creation. We maintain the open culture of a startup at our studio in Vancouver’s Centre for Digital Media where our software engineers, user-experience designers, artists and other experts in patient engagement work together.

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

PathAI’s services solve challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making accurate diagnoses for every patient, every time. The company was founded in 2016 and is based in Boston, Massachusetts.

Tilos Therapeutics is developing antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company's initial work is on antibodies specific for Latency Associated Peptide of TGF beta. Tilos was founded in 2016 and is based in Cambridge, Massachusetts.

TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, improve site selection and planning, and bring new therapies to market faster. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought. The TriNetX platform is HIPAA and GDPR compliant.

Clinithink, a London, UK-based healthcare software company. Led by CEO Chris Tackaberry, Clinithink has developed cloud-based text processing capability that can be used to support data analytics, coding and decision support in healthcare applications. Its patent-pending Clinical Language Indexing software (CLiX) uses Natural Language Processing (NLP) to construct coded output from physicians’ notes using industry data standards (ICD-9, ICD-10, and SNOMED CT).

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Healthcare professionals across the globe trust the ClearDATA HITRUST-certified cloud to safeguard their sensitive data and power their critical applications available across the major public cloud platforms. For healthcare organizations, customers receive one of the most comprehensive Business Associate Agreements (BAA) in the industry, combined with market-leading healthcare-exclusive security and compliance solutions, and multi-cloud expertise. ClearDATA’s innovative platform of solutions and services protects customers from data privacy risks, improves their data management, and scales their healthcare IT infrastructure, enabling the industry to focus on making healthcare better by improving healthcare delivery, every single day.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.

Prognos Health is a health tech company that is pushing the boundaries of healthcare analytics. The company’s platform, prognosFACTOR, has the power to query billions of lab and health records on more than 325 million de-identified patients to answer clinically-focused healthcare questions in minutes, not months. The platform enables the querying and purchasing of patient-centric, HIPAA-Compliant healthcare data from the Prognos Marketplace to address diverse applications, including cohort design, patient journey studies, health outcomes, and more. Customers include 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions that matter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond.

LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.

Arcadia is dedicated to happier, healthier days for all. We transform diverse data into a unified fabric for health. Our platform delivers actionable insights for our customers to advance care and research, drive strategic growth, and achieve financial success.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Hangzhou Just Biotherapeutics is a comprehensive high-tech design company dedicated to accelerating the development of bio-medicine and significantly reducing manufacturing costs. Their core strengths are molecular design, process design, drug product design and manufacturing plant design.

StayWell is a health engagement company that helps its clients engage and educate people to improve health and business results. We bring decades of experience working across the health care industry to design solutions that address our clients’ evolving needs. StayWell fuse expertise in health engagement and the science of behavior change with an integrated portfolio of solutions and robust content assets. Our customizable programs are proven to effectively engage people to make positive health care decisions—across even the most challenging populations. StayWell want you to know your programs are working—and see unmistakable benefits. A passion for data is at the heart of what we do and informs every stage of our work from program design to implementation to continual performance review. That’s why our clients across the health spectrum know us for results: diminished health costs, accelerated group participation, increased patient acquisition, better health outcomes and unprecedented program satisfaction.

OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious diseases. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life-threatening infections to improve patient outcomes. The company's approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). OpGen was established in 2002 by David Schwartz in Rockville, Maryland.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Hangzhou Just Biotherapeutics is a comprehensive high-tech design company dedicated to accelerating the development of bio-medicine and significantly reducing manufacturing costs. Their core strengths are molecular design, process design, drug product design and manufacturing plant design.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

medCPU, Inc. delivers real-time clinical care advice through its Advisor Button technology for hospitals in the United States. Its Advisor Button captures the clinical picture from clinicians’ free-text notes, dictations, and structured documentation entered into EMR and analyzes it against a growing library of content for generating real-time precise prompts for care consideration; medCPU platform captures the clinical picture in real time, including narrative text and structured data to deliver the clinical and compliance guidance

OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious diseases. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life-threatening infections to improve patient outcomes. The company's approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). OpGen was established in 2002 by David Schwartz in Rockville, Maryland.

Healthcare professionals across the globe trust the ClearDATA HITRUST-certified cloud to safeguard their sensitive data and power their critical applications available across the major public cloud platforms. For healthcare organizations, customers receive one of the most comprehensive Business Associate Agreements (BAA) in the industry, combined with market-leading healthcare-exclusive security and compliance solutions, and multi-cloud expertise. ClearDATA’s innovative platform of solutions and services protects customers from data privacy risks, improves their data management, and scales their healthcare IT infrastructure, enabling the industry to focus on making healthcare better by improving healthcare delivery, every single day.

Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets. Koneksa currently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2015 and is based in New York, United States.

Ayogo is a global leader in the application of behavioral psychology and social gaming to improve health outcomes for patients. Healthier patients improve financial outcomes. Insurers, healthcare providers, ACOs and pharmaceutical companies are Ayogo’s clients. All of our projects begin with meaningful collaboration with patients, end-users and clients. Our corporate culture fosters excellence and thoughtful creation. We maintain the open culture of a startup at our studio in Vancouver’s Centre for Digital Media where our software engineers, user-experience designers, artists and other experts in patient engagement work together.

NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.

Daktari Diagnostics was founded to create products that address the most pressing challenges in global health. These problems include not only better diagnosis of disease, but also the communication of data throughout the healthcare system. We are committed to delivering critical diagnostic test results to clinicians and patients across the globe. Our team of engineers, scientists, physicians, and global health experts is uniquely dedicated to making high-performance products specifically designed for resource-poor markets. We recognize that information can only be useful if it can move. Daktari’s products are connected in the field, allowing clinical, quality, and performance data to flow where it needs to go. We strive to provide quality products at an affordable price, and to support our products when used by anyone, anywhere in the world. We strive to treat our customers, our partners, and our colleagues with kindness, as equals, and to be a positive force in our communities and in the world.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Imago BioSciences is a clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians. The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases. Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives. Imago BioSciences was founded in 2012 and is based in Redwood City, California.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Healthsense is a provider of remote monitoring technology solutions for the senior care continuum. With our full range of health and safety monitoring systems, providers are empowered to proactively deliver the highest quality care possible through critical health information. Caregivers reduce costs, increase independence and enhance senior experiences when armed with the right information at the right time.

Cleveland HeartLab, Inc. is a specialty clinical laboratory and disease management company focused on novel biomarker technologies and the creation of proprietary diagnostic tests.

Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV). In July 2009, the Company completed the proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype I infected patients. Idenix selected IDX320 as its lead clinical candidate from its protease inhibitor discovery program. The Company has also developed products and drug candidates for the treatment of hepatitis B virus (HBV), human immunodeficiency virus type I (HIV) and acquired immune deficiency syndrome (AIDS).

medCPU, Inc. delivers real-time clinical care advice through its Advisor Button technology for hospitals in the United States. Its Advisor Button captures the clinical picture from clinicians’ free-text notes, dictations, and structured documentation entered into EMR and analyzes it against a growing library of content for generating real-time precise prompts for care consideration; medCPU platform captures the clinical picture in real time, including narrative text and structured data to deliver the clinical and compliance guidance

Healthcare professionals across the globe trust the ClearDATA HITRUST-certified cloud to safeguard their sensitive data and power their critical applications available across the major public cloud platforms. For healthcare organizations, customers receive one of the most comprehensive Business Associate Agreements (BAA) in the industry, combined with market-leading healthcare-exclusive security and compliance solutions, and multi-cloud expertise. ClearDATA’s innovative platform of solutions and services protects customers from data privacy risks, improves their data management, and scales their healthcare IT infrastructure, enabling the industry to focus on making healthcare better by improving healthcare delivery, every single day.

Humedica is the clinical intelligence company that powers health care providers and life sciences organ izations to make better-informed, more confident decisions by transforming unconnected data from multiple sources into real-world insights.

Prognos Health is a health tech company that is pushing the boundaries of healthcare analytics. The company’s platform, prognosFACTOR, has the power to query billions of lab and health records on more than 325 million de-identified patients to answer clinically-focused healthcare questions in minutes, not months. The platform enables the querying and purchasing of patient-centric, HIPAA-Compliant healthcare data from the Prognos Marketplace to address diverse applications, including cohort design, patient journey studies, health outcomes, and more. Customers include 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

eHealth Technologies™ (formerly eHealth Global) is a leading health care technology company that advances the delivery of life-altering care. We help to provide fast and seamless access to health care for patients by collecting medical records, test results, and images and organizing them so that physicians have the information they need to provide superior care in a timely manner – in a fast, easy-to-use, digital format. Our team members take great pride in working behind the scenes to help millions of patients benefit from faster access to lifesaving medical services ranging from cancer care to organ transplants to emergency care.

Healthsense is a provider of remote monitoring technology solutions for the senior care continuum. With our full range of health and safety monitoring systems, providers are empowered to proactively deliver the highest quality care possible through critical health information. Caregivers reduce costs, increase independence and enhance senior experiences when armed with the right information at the right time.

Remedy Informatics (formerly RemedyMD) is the leading provider of patient registries, medical research software, and research informatics products that accelerate translational medicine discoveries from bench to bedside. Remedy offers a wide range of highly configurable biomedical informatics products that are built on the powerful Mosaic™ Platform. Remedy’s mission is to tangibly, measurably and permanently improve the effectiveness of Life Science and Healthcare Research around the world.

Healthsense is a provider of remote monitoring technology solutions for the senior care continuum. With our full range of health and safety monitoring systems, providers are empowered to proactively deliver the highest quality care possible through critical health information. Caregivers reduce costs, increase independence and enhance senior experiences when armed with the right information at the right time.

Aptus Health provides digital health engagement solutions for healthcare providers and patients. Aptus Health is on a mission to dynamically connect health and life sciences companies with healthcare professionals, healthcare consumers, and other members of the healthcare ecosystem.

Daktari Diagnostics was founded to create products that address the most pressing challenges in global health. These problems include not only better diagnosis of disease, but also the communication of data throughout the healthcare system. We are committed to delivering critical diagnostic test results to clinicians and patients across the globe. Our team of engineers, scientists, physicians, and global health experts is uniquely dedicated to making high-performance products specifically designed for resource-poor markets. We recognize that information can only be useful if it can move. Daktari’s products are connected in the field, allowing clinical, quality, and performance data to flow where it needs to go. We strive to provide quality products at an affordable price, and to support our products when used by anyone, anywhere in the world. We strive to treat our customers, our partners, and our colleagues with kindness, as equals, and to be a positive force in our communities and in the world.

HTG Molecular Diagnostics is a provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company's NGS-adapted chemistry and HTG EdgeSeq technology automate sample processing and can swiftly, reliably, and concurrently profile hundreds or thousands of molecular targets utilizing a very little quantity of biological material, in liquid or solid form. Its products comprise equipment, consumables, and software that work together to form the HTG EdgeSeq platform. The HTG EdgeSeq platform automates the company's menu of HTG EdgeSeq molecular profiling panels, which use genomic sequencing techniques to swiftly provide gene expression data for clients utilizing its streamlined approach. HTG Molecular Diagnostics was established in 1997 by Bruce E. Seligmann in Tucson, Arizona.

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.

ImpactRx provides consultative and analytics-based promotional effectiveness solutions to the healthcare industry. The company tracks and evaluates the impact of pharmaceutical promotions on the prescribing behavior of physicians.

HTG Molecular Diagnostics is a provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company's NGS-adapted chemistry and HTG EdgeSeq technology automate sample processing and can swiftly, reliably, and concurrently profile hundreds or thousands of molecular targets utilizing a very little quantity of biological material, in liquid or solid form. Its products comprise equipment, consumables, and software that work together to form the HTG EdgeSeq platform. The HTG EdgeSeq platform automates the company's menu of HTG EdgeSeq molecular profiling panels, which use genomic sequencing techniques to swiftly provide gene expression data for clients utilizing its streamlined approach. HTG Molecular Diagnostics was established in 1997 by Bruce E. Seligmann in Tucson, Arizona.

VisEn Medical, Inc. designs, develops, and commercializes fluorescence in vivo imaging technology platforms. The company’s Fluorescence Molecular Tomographic (FMT) imaging systems and vivo imaging agents provide fluorescence molecular imaging performance in identifying, characterizing, and quantifying various ranges of disease biomarkers and therapeutic efficacy in vivo. It also provides ReninSense680, an imaging agent for measuring and monitoring a key hypertension and renal disease biomarker in vivo; and VivoTagR 680 XL fluorescent dye for labeling biomolecules in a range of in vitro and in vivo imaging applications. In addition, the company offers fluorescence tomographic imaging systems.

HTG Molecular Diagnostics is a provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company's NGS-adapted chemistry and HTG EdgeSeq technology automate sample processing and can swiftly, reliably, and concurrently profile hundreds or thousands of molecular targets utilizing a very little quantity of biological material, in liquid or solid form. Its products comprise equipment, consumables, and software that work together to form the HTG EdgeSeq platform. The HTG EdgeSeq platform automates the company's menu of HTG EdgeSeq molecular profiling panels, which use genomic sequencing techniques to swiftly provide gene expression data for clients utilizing its streamlined approach. HTG Molecular Diagnostics was established in 1997 by Bruce E. Seligmann in Tucson, Arizona.

Abmaxis, Inc., a biopharmaceutical company, engages in the discovery, optimization, and development of monoclonal antibody (MAb) products for human therapeutics and diagnostics.

GlycoFi is a biotech firm that develops biotherapeutics based on the glycan optimization technology. The firm aims to develop its own pipeline of therapeutic proteins and team with other drug-makers to develop products. GlycoFi has developed a protein manufacturing process using yeast-based glycolysation where the resulting proteins can be used in drug development. GlycoFi was incorporated in 2000 and is based in Lebanon, New Hampshire. As of June 6, 2006, GlycoFi, Inc. operates as a subsidiary of Merck & Co. Inc.

ImpactRx provides consultative and analytics-based promotional effectiveness solutions to the healthcare industry. The company tracks and evaluates the impact of pharmaceutical promotions on the prescribing behavior of physicians.

Medco Containment Services Inc., one of the largest mail-order pharmacy and managed-care drug companies.